Pharmacological antiarrhythmic strategies are limited due to severe side effects and ventricular proarrhythmia especially in a sizable proportion of patients with ischaemic heart disease. Despite the efficacy of amiodarone in suppressing ventricular arrhythmias in patients with structural heart disease, it can cause severe organ toxicity. Class I antiarrhythmic drugs exert proarrhythmic risk in patients that experienced a myocardial infarction. This has prompted improved catheter ablation techniques but also the search for other more specific compounds. Moreover, the implantation of implantable cardioverter defibrillators (ICD) was demonstrated in large clinical trials to reduce the incidence of sudden cardiac death and all-cause mortality and represents daily clinical practice. Some patients with an implanted ICD suffer from recurrent ventricular arrhythmias which lead to continuing ICD-shock delivery. In this case, antiarrhythmic drugs are needed to treat ventricular arrhythmias and recurrent ICD therapies.
Sapp and co-workers have very recently published the results of the Ventricular Tachycardia Ablation versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease (VANISH) trial in the New England Journal of Medicine. 1 In this trial, 259 patients with ischaemic cardiomyopathy and an implanted ICD, but still experiencing ventricular tachycardia (VT) despite antiarrhythmic drugs, were enrolled. Patients were randomly assigned into a catheter ablation group, to causally treat scar-related monomorphic VT, or into an escalated antiarrhythmic drug therapy group. The latter group was treated with an escalation to amiodarone therapy, or an increased dosage of amiodarone or addition of the class I antiarrhythmic agent mexiletine, depending on the baseline therapy. The primary composite endpoint of death, VT storm, or appropriate ICD shock occurred in 59.1% of patients in the ablation group and in 68.5% in the escalated-therapy group (P < 0.05). Neither treatment option showed superiority with regards to mortality, although the trial was not powered to assess effects on mortality. Interestingly, patients that already received amiodarone during occurrence of the index event had a significantly lower rate of the primary composite endpoint in the ablation compared to the escalated-therapy group. On the other hand, patients that where not treated with amiodarone at this time point experienced no benefit from ablation therapy. Therefore, it can be stated that patients suffering from ischaemic cardiomyopathy who already have an implanted ICD and experience recurrent VT-although treated with amiodarone-may benefit from catheter ablation. Recent trials have demonstrated promising results of catheter ablation therapy causing a reduced incidence of ICD therapy delivery in patients with a history of myocardial infarction and significant ventricular arrhythmias (e.g. SMASH-VT trial). 2 However, as a limitation in these trials, control patients were not adequately treated with escalation of pharmacological antiarrhythmic drugs. Therefore the VANISH-trial expands the current knowledge because it is the first trial to compare catheter ablation in this subgroup with escalated drug therapy as it is common in daily practice. Unfortunately, no relevant new antiarrhythmic drug has become available for these patients within the last years, which is in sharp contrast to the innovation in ablation techniques and to the increased body of knowledge on arrhythmias. ischaemic heart disease and recurrent ICD shocks due to sustained VT with a Class I level of evidence B. Moreover, catheter ablation should be considered after a first episode of sustained VT in patients with ischaemic heart disease and an ICD (Class IIa level of evidence B). The results of the VANISH-trial support these recommendations and will likely improve the level of evidence. An accompanying review by Cain & Curtis stressed a couple of critical points. 3 First of all, from their point of view the approach to ablation was very heterogeneous in this trial. Moreover, ICD programming was standardized with the use of settings that was typical for the time before 2014. However, two clinical trials have influenced ICD programming towards less aggressive standards. Therefore, the results may have to be interpreted with some caution.
My personal opinion about this trial and its clinical context is that patients need to be carefully selected and the choice of therapy should take into account available expertise. Undoubtedly, ischaemic cardiomyopathy compared to dilated cardiomyopathy is the better indication for VT ablation due to its clear substrate and easier approach in most cases. VT ablation in these patients is generally safe and ablation should be considered in patients who suffer from recurrent ventricular arrhythmias/ ICD shocks despite amiodarone therapy. Nevertheless, there is still high-recurrence rate in either therapy! Therefore, there is a remaining need and further bench and exploratory research is required to identify new antiarrhythmic targets and develop specific and potent new therapies.
There are some very interesting new therapeutic approaches in the pipeline. Increased loss of calcium from the sarcoplasmic reticulum Ca leak has been implicated in cellular mechanisms of arrhythmogenesis in both ischaemic and non-ischaemic pathologies. A novel class of drugs, that reduces this leak, stabilizing the ryanodine receptor by improving the ryanodine receptor-calstabin interaction, exerts antiarrhythmic effects in preclinical tests. Another novel target is Ca/Calmodulin kinase II which can have pro-arrhythmic effects under different pathological conditions. Inhibition of the overactive kinase has multiple promising antiarrhythmic effects by reducing the sarcoplasmic reticulum Ca leak and by reduction of the so called late Na current. This current has also been reported to cause severe arrhythmias in vitro and in vivo. Most importantly, clinical studies have demonstrated antiarrhythmic potency of late Na current inhibitors in different patient collectives and study settings. In summary, there are many promising new antiarrhythmic strategies in the pipeline that await further pre-clinical and especially clinical investigation.
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